AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 132 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $515.03 ($507.08–$520.96, $4.89M total) across 14 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Aug 13, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Neutral
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRNeutralLow
01

Why it matters

The disclosed open-market sale reduces insider share exposure by about $4.89M and may slightly pressure sentiment, but it does not provide new operational, financial, or regulatory information about United Therapeutics.

02

Market read

Traders may treat this as a minor sentiment datapoint rather than a catalyst, given the 10b5-1 pre-arrangement and lack of accompanying company news.

03

What to watch

The article specifies indirect holdings and multiple small trades across a day; traders should avoid over-interpreting directionality without additional insider activity or fundamental catalysts.

Relevance 5/10Novelty 5/10Timing: after-hours/next-session context from a Form 4 filed 2026-08-13 for sales dated 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its CEO and chairperson, Martine Rothblatt, with a stated 10b5-1 plan.

Company-level read

Ticker impact

$UTHRNeutralMedium confidence
Context

United Therapeutics CEO and chair Martine Rothblatt sold $4.89M of UTHR shares via an open-market sale under a 10b5-1 plan on 2026-08-12.

Expected impact

Likely limited, short-lived impact unless paired with other news; watch for any follow-on selling signals.

Evidence & confidence

The filing is a primary Form 4 disclosure showing sale size, timing, and 10b5-1 pre-arrangement, which typically reduces interpretive weight versus non-10b5-1 sales.

Market effects

Sector

Insider-sale disclosures can marginally influence sentiment across large-cap biotech, but this filing is company-specific and not sector-wide.

Regional

No clear regional spillover; US-listed issuer filing only.

Global

Limited global relevance because the event is a US insider transaction with no stated international operational change.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    United Therapeutics Corp

    Subject of the Form 4 insider transaction disclosure (UTHR).

  • insider
    Martine A. Rothblatt

    Chairperson and CEO who reported the sale of shares via an open-market transaction under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min